Salud financiera de hoja de balance de EPS Bio Technology

Salud financiera controles de criterios 6/6

EPS Bio Technology tiene un patrimonio de accionistas total de NT$313.2M y una deuda total de NT$13.6M, lo que sitúa su ratio deuda-patrimonio en 4.4%. Sus activos y pasivos totales son NT$565.1M y NT$251.9M respectivamente. El BAIT de EPS Bio Technology es de NT$33.7M, por lo que su ratio de cobertura de intereses es de -44. Tiene efectivo e inversiones a corto plazo que ascienden a NT$151.3M.

Información clave

4.4%

Ratio deuda-patrimonio

NT$13.63m

Deuda

Ratio de cobertura de intereses	-44x
Efectivo	NT$151.32m
Patrimonio	NT$313.21m
Total pasivo	NT$251.87m
Activos totales	NT$565.09m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Apr 16

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

Mar 20

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Feb 22

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Feb 01

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Jan 04

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

Dec 14

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$389.4M) de 4183 superan a sus pasivos a corto plazo (NT$142.2M).

Pasivo a largo plazo: Los activos a corto plazo de 4183 (NT$389.4M) superan a sus pasivos a largo plazo (NT$109.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4183 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 4183 ha pasado de 9% a 4.4% en los últimos 5 años.

Cobertura de la deuda: La deuda de 4183 está bien cubierta por el flujo de caja operativo (72.7%).

Cobertura de intereses: 4183 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de EPS Bio Technology

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.43 in 3Q 2023)

EPS Bio Technology Corp. to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: EPS: NT$0.34 (vs NT$0.18 in 2Q 2023)

Now 21% overvalued after recent price rise

EPS Bio Technology Corp. to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$0.80 per share

Dividend reduced to NT$0.80

First quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.10 in 1Q 2023)

EPS Bio Technology Corp. Approves Dividend for the Year 2023

Investor sentiment improves as stock rises 21%

Full year 2023 earnings released: EPS: NT$0.88 (vs NT$1.07 in FY 2022)

EPS Bio Technology Corp., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.21 in 2Q 2022)

EPS Bio Technology Corp. Appoints Lin, Chih-Heng as Research and Development Officer

New major risk - Dividend sustainability

Upcoming dividend of NT$0.98 per share at 4.7% yield

EPS Bio Technology Corp. Approves Dividend Proposal of 2022

Full year 2022 earnings released

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: NT$0.21 (vs NT$0.27 in 2Q 2021)

EPS Bio Technology Corp. Announces Appointment of Members of Compensation Committee

Upcoming dividend of NT$0.70 per share

Eps Bio Technology Corp. Approves Cash Dividend for the Year 2021, Payable on August 4, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.49 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.59 in 2Q 2020)

Upcoming dividend of NT$1.20 per share

First quarter 2021 earnings released: NT$0.22 loss per share (vs NT$0.18 profit in 1Q 2020)

Board of Directors Approves Proposal to Distribute Dividends

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

EPS Bio Technology Corp., Annual General Meeting, Jun 28, 2021

Full year 2020 earnings released: EPS NT$1.33 (vs NT$0.78 in FY 2019)

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.49

New 90-day low: NT$20.00

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera